Cart
sales@molnova.com
Tozasertib
CAS No. 639089-54-6
Tozasertib( MK-0457 | VX-680 | MK0457 | VX680 | VX 680 | MK 0457 )
Catalog No. M15426 CAS No. 639089-54-6
Tozasertib (MK-0457, VX-680) is a highly potent, selective and reversible Aurora kinase inhibitor with Ki of 0.6, 18 and 4.6 nM for Aurora A, B and C, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 50MG | 56 | In Stock |
|
| 100MG | 91 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTozasertib
-
NoteResearch use only, not for human use.
-
Brief DescriptionTozasertib (MK-0457, VX-680) is a highly potent, selective and reversible Aurora kinase inhibitor with Ki of 0.6, 18 and 4.6 nM for Aurora A, B and C, respectively.
-
DescriptionTozasertib (MK-0457, VX-680) is a highly potent, selective and reversible Aurora kinase inhibitor with Ki of 0.6, 18 and 4.6 nM for Aurora A, B and C, respectively; also inhibits the imatinib-resistant ABL(T315I) kinase with Kd of 5 nM, displays >100-fold selectivity for the Aurora-A kinase over 55 other kinases with the only exception FLT-3 (Ki=30 nM); blocks cell-cycle progression and induces apoptosis in a diverse range of human tumor types; causes profound inhibition of tumor growth in a variety of in vivo xenograft models.Blood Cancer Discontinued.
-
In Vitro——
-
In Vivo——
-
SynonymsMK-0457 | VX-680 | MK0457 | VX680 | VX 680 | MK 0457
-
PathwayCell Cycle/DNA Damage
-
TargetAurora Kinase
-
RecptorAuroraA|AuroraB|AuroraC|Bcr-Abl|FLT3
-
Research AreaCancer
-
IndicationBlood cancer
Chemical Information
-
CAS Number639089-54-6
-
Formula Weight464.5864
-
Molecular FormulaC23H28N8OS
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESO=C(C1CC1)NC2=CC=C(SC3=NC(NC4=CC(C)=NN4)=CC(N5CCN(C)CC5)=N3)C=C2
-
Chemical NameCyclopropanecarboxamide, N-[4-[[4-(4-methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Harrington EA, et al. Nat Med. 2004 Mar;10(3):262-7.
2. Young MA, et al. Cancer Res. 2006 Jan 15;66(2):1007-14.
3. Carter TA, et al. Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):11011-6.
4. Giles FJ, et al. Blood. 2007 Jan 15;109(2):500-2.
molnova catalog
related products
-
Ilorasertib hydrochl...
Ilorasertib hydrochloride (ABT-348 hydrochloride) is an ATP-competitive multitargeted kinase inhibitor, which inhibits Aurora C, Aurora B, and Aurora A (IC50s: 1 nM, 7 nM, 120 nM).
-
CCT129202
CCT129202 is a potent, selective, ATP-competitive pan-Aurora kinase inhibitor with IC50 of 42, 198 and 227 nM for Aurora A, Aurora B and Aurora C, respectively.
-
SC-514
SC-514 is an orally active, ATP-competitive IKK-2 inhibitor with IC50 of 3-12 μM, blocks NF-κB-dependent gene expression.
